CRON:NSD-Cronos Group Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 3.48

Change

+0.05 (+1.46)%

Market Cap

USD 1.28B

Volume

2.14M

Avg Analyst Target

USD 9.00 (+158.62%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Cronos Group Inc (CRON) Stock Analysis:
Based on the Cronos Group Inc stock forecasts from 4 analysts, the average analyst target price for Cronos Group Inc is USD 9.00 over the next 12 months. Cronos Group Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Cronos Group Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Cronos Group Inc’s stock price was USD 3.48. Cronos Group Inc’s stock price has changed by -0.20% over the past week, -0.78% over the past month and -66.47% over the last year.

About

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company ...Read More

Company Website : https://www.thecronosgroup.com

Address : 111 Peter Street, Toronto, ON, Canada, M5V 2H1

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.40

52 Week High : 15.83

Short Ratio : 6.27

52 Week Low : 3.12

Shorted Shares : 17,079,077

200 Day Moving Average : 6.40

Shorted Shares Previous Month : 17,240,182

50 Day Moving Average : 4.33

Shares Held By Insiders : 47.24%

Short Percentage : 8.81%

Shares Held by Institutions : 16.59%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

+0.07 (+0.09%)

 USD7.20B 16.70 37.25
APHA Tilray, Inc

N/A

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

+2.30 (+5.19%)

 USD3.92B N/A N/A
PCRX Pacira BioSciences Inc

-1.45 (-2.29%)

 USD2.82B 46.64 19.70
TLRY Tilray Inc

-0.12 (-2.05%)

 USD2.70B N/A N/A
CGC Canopy Growth Corporation

-0.04 (-0.54%)

 USD2.66B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

-0.06 (-0.54%)

 USD1.80B 3.39 7.38
SUPN Supernus Pharmaceuticals Inc

+0.56 (+1.92%)

 USD1.55B 19.32 9.45

ETFs Containing CRON

Symbol Name Weight Mer Price(Change) Market Cap
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.06 (-0.61%)

 USD0.81B
THCX The Cannabis ETF 0.00 % 0.75 %

+0.05 (+0.70%)

 N/A
POTX Global X Funds - Global X.. 0.00 % 0.51 %

+0.05 (+1.04%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.22% 59% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.22% 59% F 43% F
Trailing 12 Months  
Capital Gain -66.47% 38% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.47% 38% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.03% 61% D- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.03% 61% D- 48% F
Risk Return Profile  
Volatility (Standard Deviation) 61.05% 35% F 27% F
Risk Adjusted Return 14.79% 59% F 34% F
Market Capitalization 1.28B 88% B+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 37.00 32% F 24% F
Price/Book Ratio 0.97 82% B- 86% B
Price / Cash Flow Ratio -8.98 78% C+ 75% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -8.92% 77% C+ 40% F
Return on Invested Capital -10.44% 67% D+ 34% F
Return on Assets -6.45% 63% D 33% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.27 22% F 14% F
Short Percent 8.81% 31% F 19% F
Beta 1.40 33% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector